Clinical trials: Peritoneal Dialysis (PD)
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Renal Impairment, Renal Anemia of Chronic Kidney Disease
Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis
This non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis.
- Trial name
- NCT02596945
- Testing
- Methoxy polyethylene glycol epoetin beta
- Where
- Germany
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche
Risk Reduction
Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)
Since the emergence of home peritoneal dialysis as an alternative to in-center hemodialysis for chronic renal replacement therapy in the late 1970s, the percentage of dialysis patients on PD has continued to decrease each year.
- Trial name
- TEACH (NCT01204619)
- Testing
- Intensive training group
- Where
- 6 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Kook-Hwan Oh
Chronic Renal Failure, Peritoneal Membrane Disorder
Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children
Peritoneal Dialysis (PD) is the preferred treatment modality in children with end-stage renal disease. Unfortunately progressive alterations of the peritoneal membrane occur with time on PD, leading to a continuous loss of…
- Trial name
- BIOKID (NCT01632046)
- Testing
- lactate and bicarbonate buffered dialysis solutions
- Where
- 7 sites in Austria, Finland and 3 more
- Volunteers
- 42 people
- Sponsor
- Heidelberg University
Peritoneal Dialysis (PD), End Stage Renal Disease (ESRD)
DKK3 as a Biomarker of Peritoneal Fibrosis in Peritoneal Dialysis Patients
Peritoneal dialysis (PD) uses the peritoneal membrane as a natural filter to remove waste products from the blood in patients with kidney failure.
- Conditions
- Peritoneal Dialysis (PD), End Stage Renal Disease (ESRD), Peritoneal Fibrosis, Ultrafiltration Failure
- Trial name
- PERIMARK (NCT07806708)
- Testing
- Modified Peritoneal Equilibration Test and DKK3 Biomarker Measurement
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität des Saarlandes
Kidney Failure, Chronic, Peritoneal Dialysis Complication
Improving Care for Peritoneal Dialysis Patients With the CKD-PD App
Managing the hydration status in patients undergoing peritoneal dialysis (PD) is a key task for nephrologists in Thailand that is made difficult due to lack of timely access to hydration metrics including weight, blood pressure…
- Trial name
- NCT04797195
- Testing
- CKD-PD app with home monitoring equipment
- Where
- 3 sites in Thailand
- Volunteers
- 208 people
- Sponsor
- Massachusetts General Hospital
End-Stage Kidney Disease, End Stage Renal Disease (ESRD)
Dialysis Efficiency and Transporter Evaluation Computational Tool in Peritoneal Dialysis
The goal of this prospective diagnostic test (correlation) study is to develop and investigate the performance of artificial intelligence in predicting peritoneum transporter status and dialysis efficiency in adult patients…
- Conditions
- End-Stage Kidney Disease, End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis (Diagnosis), End Stage Renal Failure on Dialysis
- Trial name
- DETECT-PD (NCT06842927)
- Testing
- data collection, data report
- Where
- Hong Kong
- Volunteers
- 350 people
- Sponsor
- Tuen Mun Hospital
ESRD
The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis
This is a multi-center, controlled clinical trial study. The purpose of this study is to examine the efficacy and safety of automated peritoneal dialysis as compared with intermittent haemodialysis for ESRD patients with…
- Trial name
- URG-APD (NCT03754361)
- Testing
- automated peritoneal dialysis, IHD
- Where
- 5 sites in China
- Volunteers
- 34 people
- Sponsor
- Peking Union Medical College Hospital
Renal Failure, ESRD
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
Chronic utilization of bio-incompatible peritoneal dialysis (PD) solution has been implicated as a cause of progressive loss of peritoneal permeability and recurrent fluid overload in PD patients.
- Conditions
- Renal Failure, ESRD, Cardiovascular Disease
- Trial name
- NCT00966615
- Testing
- double-chamber bag Stay-Safe Balance system, glucose-based dialysis solution
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- Chinese University of Hong Kong
Peritoneal Dialysis (PD), Hemodialysis
Examine the Epidemiology and Outcomes of Transitions From PD-to-HD in Canada
Transitions from peritoneal dialysis to hemodialysis are common during kidney replacement therapy and may be associated with adverse outcomes.
- Conditions
- Peritoneal Dialysis (PD), Hemodialysis, Kidney Replacement Therapy
- Trial name
- UPLIFT-PD CORR (NCT07477210)
- Where
- Canada
- Volunteers
- 17,000 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Chronic Renal Failure
PD-Improved Dialysis Efficiency With Adapted APD
The aim of this study is to observe the effect of adapted APD (aAPD) on maintenance and/or improvement of the hydration status of more than 250 PD patients, and to observe the tolerability of the therapy over a long period.
- Trial name
- PD-IDEA (NCT02470598)
- Testing
- Treatment with Adapted Automated Peritoneal Dialysis (aAPD)
- Where
- 50 sites in Czechia, Denmark and 4 more
- Volunteers
- 182 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Liver Cirrhosis, Ascites
Peritoneal Dialysis Catheters for the Treatment of Refractory Ascites
One complication of liver disease is the buildup of fluid within the belly. This is known as ascites. Patients who have ascites have a decreased appetite, pain, nausea and shortness of breath.
- Trial name
- NCT02975726
- Testing
- Peritoneal Dialysis Catheter, Large Volume Paracentesis, 25% Human Serum Albumin injection
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of Manitoba
Peritoneal Dialysis, Acute Kidney Injury
Intensive Versus Regular Dosage For PD In AKI.
This is a multicenter, pilot RCT study, aiming to compare intensive dosage and regular dosage of PD for AKI patients with indications for dialysis.
- Trial name
- NCT03438877
- Testing
- Intensive dosage of PD, Regular dosage of PD
- Where
- 7 sites in China
- Volunteers
- 6 people
- Sponsor
- Peking University First Hospital
Peritoneal Dialysis Associated Peritonitis
Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Intra-peritoneal administration of antibiotics covering both gram-positive and gram-negative organisms was recommended as first-line regimen for the management of peritoneal dialysis related peritonitis.
- Trial name
- PD (NCT02787057)
- Testing
- vancomycin, moxifloxacin, ceftazidime
- Volunteers
- 80 people
- Sponsor
- Peking University First Hospital
Peritoneal Dialysis (PD), Large Language Models
A Simulated Case Study of a Peritoneal Dialysis-Specialized Large Language Model Assisting Doctors in Improving Decision-Making in Peritoneal Dialysis Management
This study is a randomized controlled trial based on simulated clinical cases, aiming to establish a standardized evaluation system for PD physicians, to assess the differences in PD management quality between a workflow assisted…
- Trial name
- NCT07724327
- Testing
- Peritoneal dialysis-specialized large language model.
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Renal Insufficiency / Therapy
PD Catheter Data Collection
Peritoneal Dialysis (PD) is a Renal Replacement Therapy for patients with renal insufficiency that has been used more frequently in recent years.
- Trial name
- Catheter (NCT07156123)
- Where
- 2 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
End-Stage Kidney Disease (ESKD), Hemodialysis
Cardiovascular and Bone Mineral Markers in Dialysis Patients and Healthy Controls
This observational study will compare cardiovascular status, bone mineral metabolism, systemic inflammation, body composition, functional status, quality of life, pruritus, and pain among patients receiving different renal…
- Conditions
- End-Stage Kidney Disease (ESKD), Hemodialysis, Peritoneal Dialysis (PD)
- Trial name
- NCT07686978
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gazi University
End Stage Renal Disease
Use of Ointments in Prevention of Catheter Related Infections in PD
Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common complication is bacterial infection or 'peritonitis'.
- Trial name
- NCT00400595
- Testing
- Mupirocin ointment, Polysporin Triple
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Anemia, Chronic Kidney Disease
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
The primary objective of study is Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2 Part B : To evaluate the proof of concept (POC) of GX-E2
- Trial name
- NCT02044653
- Testing
- GX-E2, NESP, MIRCERA
- Where
- 5 sites in South Korea
- Volunteers
- 257 people
- Sponsor
- Genexine, Inc.